Literature DB >> 28843578

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.

.   

Abstract

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2015 provides an up-to-date analysis of the burden of lower respiratory tract infections (LRIs) in 195 countries. This study assesses cases, deaths, and aetiologies spanning the past 25 years and shows how the burden of LRI has changed in people of all ages.
METHODS: We estimated LRI mortality by age, sex, geography, and year using a modelling platform shared across most causes of death in the GBD 2015 study called the Cause of Death Ensemble model. We modelled LRI morbidity, including incidence and prevalence, using a meta-regression platform called DisMod-MR. We estimated aetiologies for LRI using two different counterfactual approaches, the first for viral pathogens, which incorporates the aetiology-specific risk of LRI and the prevalence of the aetiology in LRI episodes, and the second for bacterial pathogens, which uses a vaccine-probe approach. We used the Socio-demographic Index, which is a summary indicator derived from measures of income per capita, educational attainment, and fertility, to assess trends in LRI-related mortality. The two leading risk factors for LRI disability-adjusted life-years (DALYs), childhood undernutrition and air pollution, were used in a decomposition analysis to establish the relative contribution of changes in LRI DALYs.
FINDINGS: In 2015, we estimated that LRIs caused 2·74 million deaths (95% uncertainty interval [UI] 2·50 million to 2·86 million) and 103·0 million DALYs (95% UI 96·1 million to 109·1 million). LRIs have a disproportionate effect on children younger than 5 years, responsible for 704 000 deaths (95% UI 651 000-763 000) and 60.6 million DALYs (95ÙI 56·0-65·6). Between 2005 and 2015, the number of deaths due to LRI decreased by 36·9% (95% UI 31·6 to 42·0) in children younger than 5 years, and by 3·2% (95% UI -0·4 to 6·9) in all ages. Pneumococcal pneumonia caused 55·4% of LRI deaths in all ages, totalling 1 517 388 deaths (95% UI 857 940-2 183 791). Between 2005 and 2015, improvements in air pollution exposure were responsible for a 4·3% reduction in LRI DALYs and improvements in childhood undernutrition were responsible for an 8·9% reduction.
INTERPRETATION: LRIs are the leading infectious cause of death and the fifth-leading cause of death overall; they are the second-leading cause of DALYs. At the global level, the burden of LRIs has decreased dramatically in the last 10 years in children younger than 5 years, although the burden in people older than 70 years has increased in many regions. LRI remains a largely preventable disease and cause of death, and continued efforts to decrease indoor and ambient air pollution, improve childhood nutrition, and scale up the use of the pneumococcal conjugate vaccine in children and adults will be essential in reducing the global burden of LRI. FUNDING: Bill & Melinda Gates Foundation.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28843578      PMCID: PMC5666185          DOI: 10.1016/S1473-3099(17)30396-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  48 in total

1.  Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004-2008.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-02-15

Review 2.  Pneumonia research to reduce childhood mortality in the developing world.

Authors:  J Anthony G Scott; W Abdullah Brooks; J S Malik Peiris; Douglas Holtzman; E Kim Mulholland
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients.

Authors:  S F Dowell; R L Garman; G Liu; O S Levine; Y H Yang
Journal:  Clin Infect Dis       Date:  2001-02-23       Impact factor: 9.079

4.  The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children.

Authors:  Shabir A Madhi; Locadiah Kuwanda; Clare Cutland; Keith P Klugman
Journal:  Clin Infect Dis       Date:  2005-04-07       Impact factor: 9.079

5.  A worldwide perspective of atypical pathogens in community-acquired pneumonia.

Authors:  Forest W Arnold; James T Summersgill; Andrew S Lajoie; Paula Peyrani; Thomas J Marrie; Paolo Rossi; Francesco Blasi; Patricia Fernandez; Thomas M File; Jordi Rello; Rosario Menendez; Lucia Marzoratti; Carlos M Luna; Julio A Ramirez
Journal:  Am J Respir Crit Care Med       Date:  2007-03-01       Impact factor: 21.405

Review 6.  Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings.

Authors:  Stephen M Graham; Mike English; Tabish Hazir; Penny Enarson; Trevor Duke
Journal:  Bull World Health Organ       Date:  2008-05       Impact factor: 9.408

Review 7.  Conjugate vaccines for preventing Haemophilus influenzae type B infections.

Authors:  G Swingler; D Fransman; G Hussey
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

Review 8.  Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials.

Authors:  Sunil Sazawal; Robert E Black
Journal:  Lancet Infect Dis       Date:  2003-09       Impact factor: 25.071

9.  Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers.

Authors:  Philip C Hill; Abiodun Akisanya; Kawsu Sankareh; Yin Bun Cheung; Mark Saaka; George Lahai; Brian M Greenwood; Richard A Adegbola
Journal:  Clin Infect Dis       Date:  2006-08-04       Impact factor: 9.079

10.  Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction.

Authors:  Kate E Templeton; Sitha A Scheltinga; Willian C J F M van den Eeden; A Willy Graffelman; Peterhans J van den Broek; Eric C J Claas
Journal:  Clin Infect Dis       Date:  2005-06-22       Impact factor: 9.079

View more
  206 in total

1.  Oseltamivir Treatment of Influenza in Children.

Authors:  Timothy M Uyeki
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

2.  Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks.

Authors:  Grant Waterer; Mark L Metersky
Journal:  Chest       Date:  2019-07-06       Impact factor: 9.410

3.  Why have Non-communicable Diseases been Left Behind?

Authors:  Florencia Luna; Valerie A Luyckx
Journal:  Asian Bioeth Rev       Date:  2020-03-20

4.  Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.

Authors:  Naïm Ouldali; Corinne Levy; Philippe Minodier; Laurence Morin; Sandra Biscardi; Marie Aurel; François Dubos; Marie Alliette Dommergues; Ellia Mezgueldi; Karine Levieux; Fouad Madhi; Laure Hees; Irina Craiu; Chrystèle Gras Le Guen; Elise Launay; Ferielle Zenkhri; Mathie Lorrot; Yves Gillet; Stéphane Béchet; Isabelle Hau; Alain Martinot; Emmanuelle Varon; François Angoulvant; Robert Cohen
Journal:  JAMA Pediatr       Date:  2019-04-01       Impact factor: 16.193

5.  Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.

Authors:  Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton
Journal:  J Control Release       Date:  2018-08-09       Impact factor: 9.776

6.  Effectiveness of a theory-based mobile phone text message intervention for improving protective behaviors of pregnant women against air pollution: a randomized controlled trial.

Authors:  Mehrnoosh Jasemzadeh; Morteza Abdullatif Khafaie; Nematallah Jaafarzadeh; Marzieh Araban
Journal:  Environ Sci Pollut Res Int       Date:  2017-12-19       Impact factor: 4.223

7.  Neutrophil-Derived Oncostatin M Triggers Diverse Signaling Pathways during Pneumonia.

Authors:  Katrina E Traber; Ernest L Dimbo; Anukul T Shenoy; Elise M Symer; Eri Allen; Joseph P Mizgerd; Lee J Quinton
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

8.  Surveillance Data for Eight Consecutive Influenza Seasons in Sicily, Italy.

Authors:  Fabio Tramuto; Vincenzo Restivo; Claudio Costantino; Giuseppina Maria Elena Colomba; Carmelo Massimo Maida; Alessandra Casuccio; Francesco Vitale
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

Review 9.  The Collaborative Cross mouse model for dissecting genetic susceptibility to infectious diseases.

Authors:  Hanifa Abu Toamih Atamni; Aysar Nashef; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2018-08-24       Impact factor: 2.957

10.  Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection.

Authors:  Stephanie J Bissel; Chalise E Carter; Guoji Wang; Scott K Johnson; Lauren P Lashua; Alyson A Kelvin; Clayton A Wiley; Elodie Ghedin; Ted M Ross
Journal:  Am J Pathol       Date:  2019-10-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.